Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares saw an uptick in trading volume on Thursday . 1,410,300 shares were traded during mid-day trading, an increase of 703% from the previous session’s volume of 175,527 shares.The stock last traded at $6.99 and had previously closed at $6.99.
Several brokerages have recently issued reports on SNSS. Cantor Fitzgerald set a $3.00 price target on shares of Sunesis Pharmaceuticals and gave the company a “hold” rating in a report on Monday, December 11th. UBS Group began coverage on shares of Sunesis Pharmaceuticals in a report on Monday, November 20th. They issued an “outperform” rating for the company. Oppenheimer began coverage on shares of Sunesis Pharmaceuticals in a report on Tuesday, November 21st. They issued an “outperform” rating and a $7.00 price target for the company. ValuEngine raised shares of Sunesis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, February 7th. Finally, Zacks Investment Research lowered shares of Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, February 15th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Sunesis Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $3.75.
The stock has a market cap of $227.41, a price-to-earnings ratio of -3.79 and a beta of 1.71. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of -0.34.
Several hedge funds have recently made changes to their positions in SNSS. Wells Fargo & Company MN grew its holdings in shares of Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 18,254 shares during the period. Virtu KCG Holdings LLC acquired a new position in shares of Sunesis Pharmaceuticals in the 2nd quarter valued at $208,000. Geode Capital Management LLC grew its holdings in shares of Sunesis Pharmaceuticals by 105.2% in the 4th quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock valued at $463,000 after buying an additional 64,343 shares during the period. BlackRock Inc. grew its holdings in shares of Sunesis Pharmaceuticals by 9.5% in the 4th quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock valued at $482,000 after buying an additional 11,351 shares during the period. Finally, Vatera Holdings LLC acquired a new position in shares of Sunesis Pharmaceuticals in the 4th quarter valued at $673,000. 39.64% of the stock is owned by institutional investors.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.